These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33475972)

  • 1. Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis.
    Urban ML; Bettiol A; Mattioli I; Emmi G; Di Scala G; Avagliano L; Lombardi N; Crescioli G; Virgili G; Serena C; Mecacci F; Ravaldi C; Vannacci A; Silvestri E; Prisco D
    Intern Emerg Med; 2021 Aug; 16(5):1357-1367. PubMed ID: 33475972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis.
    Bettiol A; Avagliano L; Lombardi N; Crescioli G; Emmi G; Urban ML; Virgili G; Ravaldi C; Vannacci A
    Clin Pharmacol Ther; 2021 Jul; 110(1):189-199. PubMed ID: 33423282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin for preventing adverse obstetrical outcomes in pregnant women with antiphospholipid syndrome, a systematic review and meta-analysis.
    Guerby P; Fillion A; O'Connor S; Bujold E
    J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101974. PubMed ID: 33171281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of recurrent miscarriage in women with antiphospholipid syndrome: A systematic review and network meta-analysis.
    Yang Z; Shen X; Zhou C; Wang M; Liu Y; Zhou L
    Lupus; 2021 Jan; 30(1):70-79. PubMed ID: 33081590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis.
    Liu X; Qiu Y; Yu ED; Xiang S; Meng R; Niu KF; Zhu H
    Am J Reprod Immunol; 2020 Apr; 83(4):e13219. PubMed ID: 31872490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for the prevention of fetal growth restriction: protocol for a systematic review and network meta-analysis.
    Bettiol A; Lombardi N; Crescioli G; Avagliano L; Mugelli A; Ravaldi C; Vannacci A
    BMJ Open; 2019 Jul; 9(7):e029467. PubMed ID: 31350249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
    Fouda UM; Sayed AM; Abdou AM; Ramadan DI; Fouda IM; Zaki MM
    Int J Gynaecol Obstet; 2011 Mar; 112(3):211-5. PubMed ID: 21251653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
    Hamulyák EN; Scheres LJ; Marijnen MC; Goddijn M; Middeldorp S
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012852. PubMed ID: 32358837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.
    Noble LS; Kutteh WH; Lashey N; Franklin RD; Herrada J
    Fertil Steril; 2005 Mar; 83(3):684-90. PubMed ID: 15749498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study.
    Bouvier S; Cochery-Nouvellon E; Lavigne-Lissalde G; Mercier E; Marchetti T; Balducchi JP; Marès P; Gris JC
    Blood; 2014 Jan; 123(3):404-13. PubMed ID: 24200687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature.
    Tenti S; Cheleschi S; Guidelli GM; Galeazzi M; Fioravanti A
    Autoimmun Rev; 2016 Mar; 15(3):226-35. PubMed ID: 26656906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.
    Lefkou E; Mamopoulos A; Dagklis T; Vosnakis C; Rousso D; Girardi G
    J Clin Invest; 2016 Aug; 126(8):2933-40. PubMed ID: 27454295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
    Lefkou E; Varoudi K; Pombo J; Jurisic A; Jurisic Z; Contento G; Girardi G
    Biochem Pharmacol; 2020 Dec; 182():114217. PubMed ID: 32926874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticardiolipin Positivity Is Highly Associated With Intrauterine Growth Restriction in Women With Antiphospholipid Syndrome.
    Xi F; Cai Y; Lv M; Jiang Y; Zhou F; Chen Y; Jiang L; Luo Q
    Clin Appl Thromb Hemost; 2020; 26():1076029620974455. PubMed ID: 33296221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy.
    Lee EE; Jun JK; Lee EB
    J Korean Med Sci; 2021 Jan; 36(4):e24. PubMed ID: 33496084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.
    Tektonidou MG; Andreoli L; Limper M; Tincani A; Ward MM
    RMD Open; 2019; 5(1):e000924. PubMed ID: 31168416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.
    Branch DW; Peaceman AM; Druzin M; Silver RK; El-Sayed Y; Silver RM; Esplin MS; Spinnato J; Harger J
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):122-7. PubMed ID: 10649166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials.
    Lu C; Liu Y; Jiang HL
    J Matern Fetal Neonatal Med; 2019 Apr; 32(8):1299-1311. PubMed ID: 29179589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians.
    Vayssière C; Sentilhes L; Ego A; Bernard C; Cambourieu D; Flamant C; Gascoin G; Gaudineau A; Grangé G; Houfflin-Debarge V; Langer B; Malan V; Marcorelles P; Nizard J; Perrotin F; Salomon L; Senat MV; Serry A; Tessier V; Truffert P; Tsatsaris V; Arnaud C; Carbonne B
    Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():10-8. PubMed ID: 26207980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of fetal death in the antiphospholipid antibody syndrome.
    Cowchock S
    Lupus; 1996 Oct; 5(5):467-72. PubMed ID: 8902784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.